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Abstract：Skeletal muscle is one of the most important morpho-functional organs, and its atrophy 
causes severe conditions such as muscular dystrophies. RNA interference (RNAi)-based gene therapy 
has been expected as a safe remedy without side effects. However, the rapid degradation of small 
interfering RNAs (siRNAs) and their limited duration of activity require efficient delivery methods. 
Atelocollagen (ATCOL)- or cationic liposome-mediated administration of siRNAs is a promising 
approach to disease treatment, including muscular atrophy. In thie study, we used RNAi to control 
the expression of myostatin, a negative regulator of skeletal muscle formation, for the purpose of 
developing a good as new method to regulate skeletal muscle volume, and report herein that ATCOL- 
or cationic liposome-mediated administration of a myostatin-targeting siRNA into skeletal muscles of 
normal and diseased mice induced a marked increase in muscle mass and a recovery of myofunction. 
We are now trying to examine the effectiveness of systemic administration of cationic liposome-
delivered myostatin-targeting siRNA. Since cationic liposomes delivered siRNA to muscles effectively 
and are safe and cost-effective, they may represent a powerful therapeutic tool for disease treatment, 
including muscular atrophy.
In this review, I would like to summarize about possibility to regulate skeletal muscle volume and 
to develop a new treatment for various muscle disorders by RNAi technique.
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の期待が高まりつつある 22, 23）。また，この RNAiを遺伝
子医薬として応用する利点として，標的遺伝子とは無
関係の遺伝子発現に影響を及ぼすことのない高い特異性
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